Last checked at 6 Feb 2024 14:03
genedrive plc
("genedrive" or the "Company")
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 2,050,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on 05 February 2024, being the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending June 2025. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||||
a. | Name | James Cheek CEO Russell Shaw CFO Gino Miele CSO Patrick Breen CCO Jonathan Barber Operations Director
| ||||||||||||||||||
2. | Reason for the notification | |||||||||||||||||||
a. | Position/status | See box 1a. above
| ||||||||||||||||||
a. | Initial notification /Amendment | Initial notification | ||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||
a. | Name | genedrive plc | ||||||||||||||||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||||||||||||||||
b. | Nature of the transaction | Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017 | ||||||||||||||||||
c. | Price(s) and volume(s) |
| ||||||||||||||||||
d. | Aggregated information ?Aggregated volume ?Price
|
N/A
| ||||||||||||||||||
e. | Date of the transaction | 2024-02-06 | ||||||||||||||||||
f. | Place of the transaction | Outside a trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options | ||||||||||||||||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
James Cheek: CEO / Russ Shaw: CFO | |
Peel Hunt LLP (Nominated Adviser and Broker) | +44 (0)20 7418 8900 |
James Steel / Patrick Birkholm | |
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Anna Dunphy | +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore, by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge which circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes, ensuring vital care is delivered with no negative impact on the patient pathway.
The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.